284 Poly(ADP-ribose) glycohydrolase (PARG) inhibitors increase nuclear poly(ADP-ribose) after methylating DNA damage
Allan M. Jordan(Signature Research (United States)), Donald Ogilvie(Bioscience Research), Colin Hutton(The Francis Crick Institute), Sian B Jones, Keith Smith(Swansea University), Shelby Holt(Southwestern Medical Center), Bohdan Waszkowycz(University of Manchester), James R. Hitchin, Helen Small(University of Manchester), Alexandra Stowell(University of Manchester), Ian D. Waddell(Charles River Laboratories (United Kingdom)), Emma Fairweather(University of Manchester), Nicola Hamilton(Cancer Research UK Manchester Institute), Ben Acton(Cancer Research UK Manchester Institute), Alison E. McGonagle(Cancer Research UK Manchester Institute), Dominic I. James(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|514
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
|Nature Cancer|2021|279